JAMA Network
About The Study: This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal RSV vaccine uptake was low, but nirsevimab was effective against RSV-associated hospitalization. There is a potential for substantial public health impact with increased and equitable prevention product coverage in future seasons.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
